Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented data at the International Liver Congress™ of The European Association for the Study of the Liver (EASL) in London, United Kingdom. The first analysis featured a multinational survey of patient-reported outcomes showing the effects of pruritus in patients with primary sclerosing cholangitis (PSC). A second poster assessed gastrointestinal (GI) tolerability on time of dosing with ileal bile acid transporter inhibitors (IBATis) relative to meals. “We are pleased to share new data at the 2022 EASL congress,” said Dr. Pam Vig, head of research and development at Mirum. “The large multinational PSC survey shows that adults with PSC often experie(…) Read More »